AZN.ST - AstraZeneca PLC

Stockholm - Stockholm Real-time price. Currency in SEK
628.90
-10.40 (-1.63%)
At close: 5:29PM CEST
Stock chart is not supported by your current browser
Previous close639.30
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range626.00 - 643.60
52-week range461.30 - 653.60
Volume324,266
Avg. volume302,081
Market cap788.861B
Beta0.82
PE ratio (TTM)284.06
EPS (TTM)2.21
Earnings dateN/A
Forward dividend & yield22.50 (3.53%)
Ex-dividend date2018-02-15
1y target est80.24
  • Lynparza Could Be Merck’s Long-Term Growth Driver
    Market Realist3 days ago

    Lynparza Could Be Merck’s Long-Term Growth Driver

    Merck & Company (MRK) and AstraZeneca (AZN) jointly develop and commercialize Lynparza. In June, Merck and AstraZeneca presented data from the Study 08 trial, in which a combination of Lynparza and abiraterone demonstrated an improvement in median radiologic progression-free survival (or rPFS) compared to abiraterone monotherapy.

  • Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals
    Zacks8 days ago

    Pharma Stock Roundup: LLY/AZN Alzheimer's Drug Fails, MRK's Keytruda Wins Approvals

    Eli Lilly (LLY)/AstraZeneca (AZN) discontinue two late-stage studies on Alzheimer's disease candidate, lanabecestat. Merck's Keytruda gets FDA nod for two new indications.

  • The Wall Street Journal11 days ago

    [$$] Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials

    AstraZeneca PLC and Eli Lilly & Co. on Tuesday scrapped two late-stage trials of an experimental Alzheimer’s drug they were co-developing, the latest blow in the long quest to find a breakthrough for the memory-robbing disorder. The companies said the decision was taken after an independent data-monitoring committee concluded that trials associated with lanabecestat, the experimental drug, wouldn’t achieve their original goals. An AstraZeneca spokesman said the two will continue to jointly pursue an early-stage trial of another experimental Alzheimer’s drug.

  • AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap
    Investor's Business Daily11 days ago

    AstraZeneca, Lilly Join Others On Failed Alzheimer's Drug Heap

    AstraZeneca and Eli Lilly became the latest Tuesday in a series of firms to scrap studies of a potential Alzheimer's disease treatment that appeared unlikely to work.

  • Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate
    Zacks11 days ago

    Lilly & AstraZeneca Scrap Studies on Alzheimer's Candidate

    Eli Lilly (LLY) and AstraZeneca (AZN) are discontinuing two late-stage studies on their Alzheimer's disease candidate, lanabecestat.

  • Alzheimer's Research Stumbles Again: What's the Road Ahead?
    Zacks11 days ago

    Alzheimer's Research Stumbles Again: What's the Road Ahead?

    The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.

  • Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests
    Bloomberg12 days ago

    Another Alzheimer's Drug Fails as Lilly, Astra Halt Tests

    Eli Lilly & Co. and AstraZeneca Plc ended two late-stage trials of an experimental drug for Alzheimer’s disease after the treatment failed to show any signs of working, adding to a litany of disappointments for the memory-robbing illness. An independent data monitoring committee found that the medicine, lanabecestat, was unlikely to meet the goals of the studies, one for early Alzheimer’s and the other for mild dementia related to the disease, the companies said in a statement Tuesday. Many researchers now believe that administering drugs after amyloid has built up in the brain may come too late to affect Alzheimer’s progress.

  • AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer
    Zacks12 days ago

    AstraZeneca's Tagrisso Wins EU Nod for First-Line Lung Cancer

    AstraZeneca's (AZN) Tagrisso gets an EU nod for first-line treatment of advanced or metastatic non-small cell lung cancer in patients with epidermal growth factor receptor (EGFR) mutations.

  • What’s in AstraZeneca’s Research Pipeline for Fiscal 2019
    Market Realist12 days ago

    What’s in AstraZeneca’s Research Pipeline for Fiscal 2019

    In the second half of fiscal 2018, major news is expected for indications in diabetes, anemia, COPD (chronic obstructive pulmonary disease), and lupus in AstraZeneca’s (AZN) pipeline. A data readout is expected from the DECLARE trial for Farxiga for type 2 diabetes, and a regulatory decision in the European Union is expected for the Bydureon autoinjector for type 2 diabetes.

  • A Look At AstraZeneca’s Research Pipeline
    Market Realist12 days ago

    A Look At AstraZeneca’s Research Pipeline

    Investors have a lot to watch for in AstraZeneca’s (AZN) research pipeline in the second fiscal quarter. The company expects a data readout for Lynparza in an ovarian cancer indication. A regulatory decision is expected for Tagrisso in the European Union for lung cancer.

  • Analyzing AstraZeneca’s Cash Flow and Valuation
    Market Realist12 days ago

    Analyzing AstraZeneca’s Cash Flow and Valuation

    In the first quarter, AstraZeneca’s (AZN) cash outflow from operating activities rose YoY (year-over-year) to $140 million from $88 million, due to an increase in the movement of working capital and higher short-term provisions for the launch of new medicines. AstraZeneca generated $273 million from investing activities in the first quarter, compared with $146 million in Q1 2017. This change was due to lower capital expenditure and the timing of receipts on disposal of intangible assets.

  • What to Expect for AstraZeneca in Fiscal 2018
    Market Realist15 days ago

    What to Expect for AstraZeneca in Fiscal 2018

    AstraZeneca (AZN) has maintained its guidance for fiscal 2018. This expected growth in product sales is weighted towards the second half of the year, reflecting the impact of generic competition for Crestor in Europe and Japan and an increased revenue contribution from new medicines. AstraZeneca expects the sum of externalization revenue and other operating income and expenses to fall YoY (year-over-year).

  • How AstraZeneca Performed in the First Quarter
    Market Realist15 days ago

    How AstraZeneca Performed in the First Quarter

    In the first quarter, AstraZeneca’s (AZN) sales were boosted by strong product launches and newer medicines and partially offset by a decrease in Crestor sales. AstraZeneca’s total revenue fell 4% YoY (year-over-year) to $5.2 billion in Q1 2018. AstraZeneca expects to return to growth in fiscal 2018.

  • Analysts’ Recommendations for AstraZeneca and Peers
    Market Realist15 days ago

    Analysts’ Recommendations for AstraZeneca and Peers

    Investors have a lot to watch for when it comes to AstraZeneca (AZN) stock, with key events expected in the company’s research pipeline and higher uptake expected for the company’s new medicines on the market. In this series, we’ll explore what analysts think of AstraZeneca’s stock potential, financial performance, valuation, and more. Of the six analysts covering AstraZeneca, four have recommended “buy” or a higher rating, while two have recommended “hold.” Their mean rating for the stock is 1.8, and their target price is $39.09.

  • 3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry
    Zacks19 days ago

    3 Stocks Raising Hopes in Troubled Large-Cap Pharma Industry

    Though the large-cap pharma industry is struggling currently, there are a few stocks that are performing well.

  • How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock?
    Simply Wall St.22 days ago

    How Does AstraZeneca PLC (LON:AZN) Fare As A Dividend Stock?

    A sizeable part of portfolio returns can be produced by dividend stocks due to their contribution to compounding returns in the long run. Over the past 10 years, AstraZeneca PLCRead More...

  • AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why
    Zacks24 days ago

    AstraZeneca (AZN) Stock on Growth Path This Year: Here's Why

    AstraZeneca's (AZN) stock is up this year while the Large-Cap Pharma industry is witnessing a decline

  • Reuters25 days ago

    AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

    (Reuters) - AstraZeneca's (AZN.L) first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive ...

  • Reuters - UK Focus25 days ago

    AstraZeneca drug Fasenra fails to achieve main goal in COPD trial

    AstraZeneca's first respiratory biological medicine Fasenra failed to meet its main target in a second clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease ...

  • AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study
    Zacks26 days ago

    AstraZeneca's Imfinzi Improves Survival in Lung Cancer Study

    AstraZeneca Plc. (AZN) announces positive overall survival (OS) data from an interim analysis of a phase III PACIFIC study evaluating its oncology candidate, Imfinzi.

  • Reuterslast month

    AstraZeneca cancer drug hits second goal by extending survival

    AstraZeneca's (AZN.L) immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer.

  • Reuters - UK Focuslast month

    AstraZeneca cancer drug hits second goal by extending survival

    AstraZeneca (NYSE: AZN - news) 's immunotherapy drug Imfinzi has hit a second important goal by improving overall survival in lung cancer patients, boosting prospects for a medicine that has already got off to a promising commercial launch. Imfinzi is the first immunotherapy to be approved in this setting, giving AstraZeneca a chance to intervene relatively early in lung cancer. Analysts believe using Imfinzi in stage III lung cancer, where cancer has only spread locally, opens up a multibillion-dollar sales opportunity and the latest overall survival (OS) data should underline the drug's potential.

  • MarketWatchlast month

    U.K. stocks log record close as U.S.-China ease trade-war tensions

    U.K. stocks rose sharply on Monday, scoring a record close, as traders welcomed news over the weekend that China and the U.S. reached an agreement that eases trade tensions between the world’s two largest economies. The FTSE 100 index (^FTSE) rose 1% to end at 7,859.17, taking out its previous closing high of 7,787.97, hit last Thursday. A weaker pound tends to boost the FTSE 100, as the index’s components conduct the bulk of their business overseas and a softening in sterling lifts revenue when converted back into the U.K. currency.

  • AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia
    Zackslast month

    AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

    AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

  • AstraZeneca potassium drug finally approved, threatening Vifor
    Reuterslast month

    AstraZeneca potassium drug finally approved, threatening Vifor

    The decision by U.S. regulators to finally approve AstraZeneca's (AZN.L) much-delayed excess potassium drug Lokelma gives the group another new medicine launch, boosting its portfolio as it strives to offset declining sales of older products. The U.S. Food and Drug Administration (FDA) had turned down the drug, formerly known as ZS-9, two times previously, casting doubt over AstraZeneca's decision to buy its original developer ZS Pharma for $2.7 billion (2 billion pounds) in 2015. Analysts, reacting to the approval announced late on Friday, said on Monday that the label for Lokelma was modestly better than for Vifor Pharma's (VIFN.S) rival therapy Veltassa, which also treats excess potassium levels or hyperkalemia.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes